Efficacy and safety of Suprachoroidal Triamcinolone Acetonide in cases of resistant diabetic Macular Edema

To evaluate the safety and efficacy of Suprachoroidal Triamcinolone Acetonide (SCTA) injection in patients with treatment resistant Diabetic Macular Edema (DME). This was a prospective non randomized interventional study conducted in the vitreoretinal department of Al Ehsan Welfare Eye Hospital, Lah...

Full description

Saved in:
Bibliographic Details
Published in:Pakistan journal of medical sciences 2020-01, Vol.36 (2), p.42-47
Main Authors: Tayyab, Haroon, Ahmed, Chaudhry Nasir, Sadiq, Muhammad Ali Ayaz
Format: Article
Language:English
Subjects:
Aflibercept
Biological products industry
Biotechnology industries
Care and treatment
Cataracts
Diabetes
Diabetic retinopathy
Diabetics
Edema
Endothelial growth factors
FDA approval
Glucocorticoids
Insulin
Lasers
Original
Patients
Pharmaceutical industry
Povidone
Ranibizumab
Reason
Researchers
Steroids
Triamcinolone
Type 2 diabetes
Vascular endothelial growth factor
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the safety and efficacy of Suprachoroidal Triamcinolone Acetonide (SCTA) injection in patients with treatment resistant Diabetic Macular Edema (DME). This was a prospective non randomized interventional study conducted in the vitreoretinal department of Al Ehsan Welfare Eye Hospital, Lahore, Pakistan from March 2018 to September 2018. A total of 24 eyes of 24 patients were included. Baseline Best Corrected Visual Acuity (BCVA), Intra Ocular Pressure (IOP) and Central Subfield Thickness (CST) was recorded. After SCTA, patient was followed up at one and three months and same clinical parameters were recorded again and results analyzed. Out of 24 patients, 11(45.83%) were males and 13(54.16%) were females. Mean pre injection CST was 636.5 ± 200.11 um. Mean pre injection BCVA was 0.8 ± 0.24 on ETDRS chart. Mean post injection CST at one and three months was 304.54 ± 67.43 and 302.66 ± 66.93 um. Mean post injection BCVA at one and three months was 0.47 ± 0.3 and 0.45 ± 0.27 on ETDRS chart. The results were statistically significant for pre and post injection CST at both one and three months ( -value < 0.00001). Pre and post injection BCVA was also statistically significant ( -value < 0.05). Preliminary evidence suggests that SCTA is well tolerated and may help in improving functional and structural outcomes of treatment resistant DME.
ISSN:1682-024X
1681-715X
DOI:10.12669/pjms.36.2.1194